Ampligen Launch For Chronic Fatigue Syndrome Could Come In Late 2007
This article was originally published in The Pink Sheet Daily
Executive Summary
NDA is on track for filing by year-end, with Hemispherx planning to seek a priority review, CEO tells “The Pink Sheet” DAILY.
You may also be interested in...
Hemispherx Submits NDA For First-Ever Chronic Fatigue Syndrome Therapy
Complete Ampligen NDA was submitted to FDA Oct. 10, CEO Carter tells “The Pink Sheet” DAILY.
Hemispherx Submits NDA For First-Ever Chronic Fatigue Syndrome Therapy
Complete Ampligen NDA was submitted to FDA Oct. 10, CEO Carter tells “The Pink Sheet” DAILY.
Ampligen NDA Could Benefit From Increased CDC Attention To Fatigue
CDC research could highlight the need for approval of Hemispherx’ chronic fatigue therapy, the company says.